Shionogi & Co., Ltd. (SGIOY)
Chart Events
Performance Outlook
| Previous Close | 12.93 |
| Open | 13.07 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 12.65 - 13.07 |
| 52 Week Range | 11.49 - 16.89 |
| Volume | 113,182 |
| Avg. Volume | 158,222 |
| Market Cap | 15.396B |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | 14.55 |
| EPS (TTM) | 0.88 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.25 (1.91%) |
| Ex-Dividend Date | Sep 28, 2020 |
| 1y Target Est | N/A |
- Reuters
Japan, eyeing Olympics, lines up half-billion doses of COVID-19 vaccine
Japan is making an aggressive move to grab enough coronavirus vaccine to inoculate its population four times over, a push the government hopes will instil confidence that it can host a delayed summer Olympics next year. Like other rich countries, Japan is signing multiple deals because some of the vaccines could fail in clinical trials or require more than one dose, an approach some experts consider prudent. Chief Cabinet Secretary Yoshihide Suga, the top government spokesman, said Japan was working with Olympic organisers on how to go ahead with the Games, tying the effort to the need to secure a vaccine.
- Reuters
CORRECTED-(OFFICIAL)-GSK says long-acting HIV prevention drug 66% more effective than Truvada
Britain's GSK said on Tuesday that an injection of its cabotegravir drug given every two months was found to be 66% more effective in preventing HIV infections than Gilead's Truvada daily oral pills. HIV incidence rate - or the number of people who contract the infection in a period - was 0.41% with the injection, compared with 1.22% with Gilead's Truvada, final data from a study presented at the virtual AIDS conference showed. Truvada is currently the standard of care for preventing HIV, but GSK hopes to challenge its dominance by making shorter, long-lasting regimens and less toxic alternatives through its ViiV Healthcare unit.
